Table 5.
Survival time of F98 glioma bearing Fischer rats treated with platinum-based drugs through different administration routes
| Drugs | Median survival time (days)
|
|||
|---|---|---|---|---|
| CED | i.v.33 | i.a.b33 | i.a. + BBBDc33 | |
| 5% Dextrose | 23.5 | 22.5 (P=0.7679)a | 22.0 (P=0.2323) | 27.0 (P=0.0272) |
| 5% Dextrose + 15 Gy | 30.0 | 30.0 (P=0.5355) | 36.5 (P=0.0825) | 36.0 (P=0.0030) |
| Cisplatin | 35.5 | 17.0 (P<0.0001) | 13.0 (P<0.0001) | -- |
| Cisplatin + 15 Gy | 39.0 | -- | -- | -- |
| Lipoplatin™ | 26.5 | 24.0 (P=0.0022) | 30.0 (P=0.2310) | 29.0 (P=0.0979) |
| Lipoplatin™ + 15 Gy | -- | 29.0 | 36.0 | 33.5 |
| Carboplatin | 38.5 | 23.5 (P<0.0001) | 29.5 (P=0.0011) | 33.5 (P=0.0078) |
| Carboplatin + 15 Gy | 54.0 | 31.0 (P<0.0001) | 46.0 (P=0.1254) | 36.0 (P=0.0158) |
a
P values were calculated by comparing to the same treatment but by CED routes of delivery.
b
i.a. delivery through the right carotid artery
c
BBBD is achieved by infusing of 25% mannitol before i.a. injection of platinum-based drugs